Point72 Hong Kong’s Denali Therapeutics DNLI Stock Holding History

Point72 Hong Kong’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-3,175	Closed	-$64.7K	–	523
2024 Q4	$64.7K	Buy	+3,175	New	+$81.3K	﹤0.01%	323
2022 Q4	–	Sell	-4,753	Closed	-$146K	–	517
2022 Q3	$146K	Buy	+4,753	New	+$155K	0.01%	1130
2022 Q2	–	Sell	-1,194	Closed	-$38K	–	2025
2022 Q1	$38K	Sell	1,194 -125	-9%	-$4.3K	﹤0.01%	1407
2021 Q4	$59K	Buy	1,319 +420	+47%	+$19.9K	﹤0.01%	1301
2021 Q3	$45K	Buy	+899	New	+$50.7K	﹤0.01%	1546
2020 Q2	–	Sell	-120	Closed	-$2K	–	1196
2020 Q1	$2K	Buy	+120	New	+$2.5K	﹤0.01%	843
2018 Q1	–	Sell	-13,043	Closed	-$204K	–	956
2017 Q4	$204K	Buy	+13,043	New	+$234K	0.16%	55

Other funds holding DNLI

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Point72 Hong Kong's DNLI Position: Q1 2025 in Review

Point72 Hong Kong sold out of Denali Therapeutics (DNLI) in Q1 2025, closing a stake of 3,175 shares — an estimated $64.7K sold.

Point72 Hong Kong first reported a position in DNLI in Q4 2017 and held it in 7 quarters. The position peaked at $204K in Q4 2017. 222 funds tracked by Wall St. Rank hold DNLI as of Q1 2025.

Point72 Hong Kong reported no remaining Denali Therapeutics position as of Q1 2025 after selling out during the quarter.
Point72 Hong Kong sold 3,175 Denali Therapeutics shares in Q1 2025, an estimated $64.7K.
Point72 Hong Kong first reported a position in Denali Therapeutics in Q4 2017 and held it in 7 quarters.
Point72 Hong Kong's Denali Therapeutics position peaked at $204K in Q4 2017.
222 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2025.

Based on Point72 Hong Kong's 13F filing for Q1 2025, filed 15 May 2025.